Abstract:Abstract Background Despite advancements, understanding the tissue pharmacokinetics of Anti-tumour necrosis factor alpha monoclonal antibodies (aTNF) and addressing cases of primary non-response, secondary loss of response, and unexplained treatment failures in some patients pose ongoing challenges. The aim of this study was to investigate factors associated with intestinal tissue levels of aTNF, anti-drug antibodies and cytokines in paediatric patients with Crohn's Disease (CD). Methods A prospective study of paediatric CD patients treated with aTNF, who underwent ileocecal resection or colonoscopy between June 2020 and January 2023 was performed. Tissue drug levels of aTNF, anti-drug antibodies and pro-inflammatory cytokines ((TNF alpha (TNF-α), interleukin-17 (IL-17), interleukin-1 beta (IL-1β), interferon gamma (IFN-γ)) were analysed in tissue culture supernatant using ELISA. Logistic regression estimated odds ratios (OR) adjusted for potential confounding from disease localization, way of sampling, presence of inflammation, and type of anti TNF (aOR). Results Twenty-seven CD patients (18 females, 66.7%) with a median disease duration of 50 (Interquartile range [IQR] 23 – 69) months were analysed. Fourteen (52%) received adalimumab (ADA), thirteen (48%) received infliximab (IFX), with a median aTNF therapy duration of 17 (IQR 4.5 – 41.5) months. Tissue aTNF detection was 100% in ADA-treated and 81.8% in IFX-treated patients. A positive association between intestinal inflammation and the level of free aTNF in tissue was observed (aOR=3.03, 95% CI=0.82-5.29). The ratio of aTNF level in tissue to serum was higher in the inflamed tissue (aOR=0.21, 95% CI=0.039-0.38). Despite an adequate level of aTNF in the serum, no measurable level was detected in the tissue in 13 patients. When comparing anti-drug antibodies levels in serum and tissue, we found a notable discrepancy, with 19 patients having undetectable serum levels, while tissue levels were measurable. We found higher tissue IL-17 levels in patients who had been treated with aTNF therapy for a longer period (aOR=0.15, 95% CI=0.031-0.274), independent of disease duration and patient age. An association was found between the level of IFN-γ and the duration of follow-up, as well as with the duration of aTNF administration. However, it was not possible to determine which of these associations is responsible for this relationship. Conclusion Our study highlights significantly elevated free drug levels in inflammatory tissue compared to non-inflammatory tissue. Our findings also align with recent insights linking aTNF failure to upregulation of mucosal IL17, providing a possible molecular rationale for improved treatment response with treatment targeting the IL-23 receptor after aTNF treatment failure.

WITHDRAWN: Anti-TNF-induced IL-27 modulates regulatory T cell responses in patients with IBD that respond to therapy

WITHDRAWN: Tanshinone II-A, a Putative Modulator Can Regulate Pro-Inflammatory and Anti-Inflammatory Cytokines in Inflammatory Conditions in RAW264.7 Cells

Parecoxib Inhibits Inflammatory Responses in a Mouse Model of Sepsis (withdrawal of Vol 12, Pg 332, 2022) (withdrawn Publication. See Vol. 12, Pg. 332, 2022)

WITHDRAWN: IL-17C plays a role in the pathophysiology of acute recurrent tonsillitis

Retracted: In Silico Characterization of Growth Differentiation Factors as Inhibitors of TNF-Alpha and IL-6 in Immune-Mediated Inflammatory Disease Rheumatoid Arthritis

WITHDRAWN: Exposure to an enriched environment improves colonic epithelial barrier integrity and attenuates mouse experimental colitis by modulating a Myc-driven gene regulatory network

withdrawn The anti-inflammatory effects of apocynin, inhibitor of NADPH oxidase, contrasting hyaluronic acid on articular cartilage during the development of osteoarthritis in a rabbit model.

Retracted: Identification of Peptides as Novel Inhibitors to Target IFN-γ, IL-3, and TNF-α in Systemic Lupus Erythematosus

[Retracted] A disintegrin and metallproteinase 15 knockout decreases migration of fibroblast‐like synoviocytes and inflammation in rheumatoid arthritis

WITHDRAWN: Effects of ethyl acetate fraction of leaf on liver function, kidney function, and cytokines level of induced rheumatoid arthritis in albino rats

TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expression

WITHDRAWN: Retinal Microvasculature Alteration in Patients with Rheumatoid Arthritis

P853 Factors associated with intestinal tissue levels of anti-TNF in pediatric patients with Crohn's Disease

WITHDRAWN: Mitochondrial genome variation affects humoral and cell-mediated innate immune responses and infection outcomes

WITHDRAWN: The Molecular Signature Associated with Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer

Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease

Retracted: MiR-502 Suppresses TNF-α-Induced Nucleus Pulposus Cell Apoptosis by Targeting TARF2

WITHDRAWN: How antimicrobial heteroresistance promotes bacterial adaptation to antimicrobial therapy – or not

WITHDRAWN: Immunological parameters of Proteus mirabilis isolates in Rheumatoid Arthritis patients with urinary tract infections

TNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability

P085 Tc17 cells with a distinct immune signature do not correlate with response to therapy with ustekinumab or TNF antibodies in active Crohn’s Disease